N/A N=601 Genetic Testing for Type 2 Diabetes
Diabetes Mellitus
Primary: Weight — 103.8; 100.7 kg — p=0.44
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=6 Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
Breast Carcinoma · Colon Carcinoma · Malignant Solid Neoplasm
Primary: Identify Cancer Patients Who Meet Criteria for Genetic Counseling and Testing — 100; 48 patients
N/A N=112 Streamlined Genetic Testing in Prostate Cancer
Prostate Cancer
Primary: Number of Participants Completing Genetic Testing — 22; 15; 31; 39 Participants — p=0.14
N/A N=531 Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
Gastrointestinal Cancer
Primary: Feasibility: Number and Percentage of Participants Who Had Their Pharmacogenetic Tests Returned Prior to Initial Dose — 130; 95 Participants
N/A N=110 Pharmacogenetic Testing Among Home Health Patients
Adverse Drug Events · Adverse Drug Reactions · Drug Interaction Potentiation
Primary: Number of Re-hospitalizations at 30 and 60 Days — 0.38; 0.25; 0.7; 0.33 Re-hospitalizations — p=0.21
Phase 4 N=28 Implementation of PPI Medication PGX Testing
Gastroesophageal Reflux
Primary: Count of Patients Agreeing to Volunteer for the Study — 28 Participants
N/A N=263 Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)
Venous Thromboembolism · Bleeding
Primary: The Number of Participants With Adverse Events Associated With Warfarin Anticoagulation Following Total Hip and Total Knee Replacement — 2; 4 participants
N/A N=383 Clinical Implementation of Carrier Status Using Next Generation Sequencing
Genetic Disorders
Primary: Number of Patients That Receive Carrier Testing and Have Results to Return — 9; 155 Participants
N/A N=601 Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer
Advanced Malignant Neoplasm · Locally Advanced Malignant Neoplasm
Primary: Change of Scores on Cancer Genetic Knowledge Scale From Baseline to Post-genetic Education — 1.43; -0.80 score on a scale — p=<.0001
N/A N=1,097 Prenatal Genetic Diagnosis by Genomic Sequencing
Fetal Structural Anomalies
Primary: Number of Participants Who Had Reportable Variants — 114; 22 Participants
N/A N=93 Development and Implementation of Electronic Decision Aids for Genetic Testing in Inherited Cancer Syndromes
Genetic Testing
Primary: Participant Satisfaction With How Educational Information is Presented in the Decision Aid — 1; 3; 29; 55 Participants
Phase 4 N=359 Clinical and Economic Implications of Genetic Testing for Warfarin Management
Blood Coagulation Disorders
Primary: Inpatient Length of Stay — 6.8; 7.2 days
N/A N=3,073 Broadening the Reach, Impact, and Delivery of Genetic Services
Cancer · Risk Reduction Behavior
Primary: Completion of Genetic Testing From Electronic Health Record — 191; 206 Participants
N/A N=115,484 Early Detection of GEnetic Risk (EDGE)
Genetic Predisposition
Primary: Rates of Screening — 9892; 3813 Participants — p=0.0074
N/A N=408 Integrating Pharmacogenetics In Clinical Care
Cardiovascular Disease
Primary: 12-Month Change in LDL Cholesterol — -1.1; -2.2 mg/dL
N/A N=685 An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Treatment Resistant Depression · Generalized Anxiety Disorder
Primary: Change From Baseline in Clinical Global Impressions Improvement (CGI-I) Scale at 3 Months — 545; 386 Participants
N/A N=53 Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
Pharmacogenetic Testing
Primary: Clinical Global Impression — 4.07; 3.96 units on a scale — p=<0.05
N/A N=190 Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting
Pharmacogenetics
Primary: Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting — 14; 13 Participants
N/A N=2,050 Genetic Testing to Understand and Address Renal Disease Disparities
Hypertension · Chronic Kidney Disease · Genomics
Primary: Number of Participants With Urine Protein Excretion — 33; 278; 39; 50 Participants
N/A N=200 Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease
Coronary Heart Disease, Susceptibility to, 5 · Prediabetic State
Primary: Dietary Intake as Measured by Percent Energy From Fat — 33.75; 34.9; 33.72; 35.05 percent energy from fat — p=0.1073
N/A N=1,874 Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy
Chronic Kidney Disease · Hypertension
Primary: Change in Systolic Blood Pressure From Baseline to 3 Months for APOL1 Negative Participants — -3.7; -3.1 mmHg — p=0.4852
N/A N=159 Genetically Guided Statin Therapy
Hypercholesterolemia · Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Primary: Morisky Medication Adherence Scale (MMAS) Score — 6.8; 6.9; 6.8; 7.1 units on a scale — p=0.96
N/A N=50 Feasibility Clinical Study of Targeted and Genome-Wide Sequencing
Solid Tumors
Primary: Time From Patient Recruitment to Final Results ≤ 21 Days in ≥ 90% of Patients — 21 calendar days
N/A N=57 Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video
Breast Cancer
Primary: Rate of Genetic Counseling and Testing Uptake. — 18; 15; 7; 12 Participants
N/A N=148 Implementation of Genomics in Substance Use Disorder Treatment
Tobacco Use Disorder · Smoking Cessation · Tobacco Use Cessation
Primary: Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days — 11; 9; 9; 2 Participants
N/A N=11 Familial Hyperlipidemia Family Registry
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants
N/A N=1,223 DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.
Death, Sudden, Cardiac · Ventricular Fibrillation · Tachycardia
Primary: Number of Patients With Ventricular Arrhythmia <400 Msec. by GNAS c.393C>T Genotype — 63; 136; 98 participants with VT < 400 msec
N/A N=38 Evaluation of Videoconferencing Versus Telephone Genetic Counseling
Remote Consultation, Teleconsultation · Remote Consultation, Video
Primary: Assessment of Knowledge Retention of Genetic Counseling Information Via 8-Question Pre- and Post-Counseling Assessment — 5.63; 4.37; 6.50; 4.74 Number of correct answers…
Phase 2 N=80 The Moran AMD Genetic Testing Assessment Study
Age-Related Macular Degeneration · Genetic Testing · Nutritional Biomarkers
Primary: Change in Skin Carotenoid Status in Response to Genetic Risk Disclosure as Measured by Reflectance Spectroscopy — 257.7; 290.9 Reflection units (RU)
N/A N=50 Improving Germline Testing in At-Risk Patients With Prostate Cancer
Prostate Cancer
Primary: Number of Participants Agreeing to Proceed With Germline Testing Among Those Approached With the Educational Intervention. — 41 Participants